Cencora executive chairman Steven Collis sells $4.1 million in stock

Cencora, Inc. (NYSE:COR) Executive Chairman Steven H. Collis recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Collis sold 14,579 shares of Cencora common stock on April 22, 2025, at an average price of $281.81 per share, amounting to a total transaction value of approximately $4.1 million. This sale was conducted under a Rule 10b5-1 trading plan adopted by Collis in November 2024. The transaction comes as Cencora, with a market capitalization of $55.25 billion, trades near its 52-week high of $296.65. InvestingPro analysis shows the stock has demonstrated low price volatility with a beta of 0.54.

In addition to the sale, Collis exercised options to acquire 12,579 shares of common stock at an exercise price of $86.09 per share. Following these transactions, Collis’s direct ownership in Cencora stands at 315,912.665 shares. These moves come as part of Collis’s ongoing management of his equity holdings in the company. According to InvestingPro, Cencora currently trades at a P/E ratio of 39.8x, and investors can access 15 additional key insights about the company’s valuation and performance through the comprehensive Pro Research Report.

In other recent news, Cencora Inc. has experienced several noteworthy developments. Mizuho (NYSE:MFG) Securities raised its price target for Cencora to $305, maintaining an Outperform rating, following the launch of a biosimilar product and strong earnings from its largest customer, Walgreens. This positive outlook is bolstered by Cencora’s strategic acquisition of RCA ophthalmology and minimal exposure to tariffs. Additionally, Mizuho revised Cencora’s fiscal year 2025 earnings per share estimate upwards to $15.50, slightly ahead of the consensus. In corporate governance news, Cencora’s shareholders approved executive compensation and elected directors during the company’s recent Annual Meeting. Ernst & Young LLP was also ratified as the independent registered public accounting firm for fiscal year 2025. Meanwhile, Leerink Partners increased their price target for Cencora to $301, citing strong first-quarter fiscal year 2025 results and a robust pharmaceutical distribution segment. Despite some international segment weakness, Leerink remains optimistic about Cencora’s business trajectory, as reflected in the updated valuation multiple.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.